These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31400225)

  • 1. A novel vaccine platform using glucan particles for induction of protective responses against Francisella tularensis and other pathogens.
    Abraham A; Ostroff G; Levitz SM; Oyston PCF
    Clin Exp Immunol; 2019 Nov; 198(2):143-152. PubMed ID: 31400225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection induced by a Francisella tularensis subunit vaccine delivered by glucan particles.
    Whelan AO; Flick-Smith HC; Homan J; Shen ZT; Carpenter Z; Khoshkenar P; Abraham A; Walker NJ; Levitz SM; Ostroff GR; Oyston PCF
    PLoS One; 2018; 13(10):e0200213. PubMed ID: 30296254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A glucan-particle based tularemia subunit vaccine induces T-cell immunity and affords partial protection in an inhalation rat infection model.
    Whelan AO; Flick-Smith HC; Walker NJ; Abraham A; Levitz SM; Ostroff GR; Oyston PCF
    PLoS One; 2024; 19(5):e0294998. PubMed ID: 38713688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.
    Baron SD; Singh R; Metzger DW
    Infect Immun; 2007 May; 75(5):2152-62. PubMed ID: 17296747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination strategies for Francisella tularensis.
    Isherwood KE; Titball RW; Davies DH; Felgner PL; Morrow WJ
    Adv Drug Deliv Rev; 2005 Jun; 57(9):1403-14. PubMed ID: 15919131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tularemia vaccine strain is a potential vector].
    Pavlov VM; Mokrievich AN; Noskov AN; Urakov NN
    Vestn Ross Akad Med Nauk; 1997; (6):30-2. PubMed ID: 9289276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nature of protective immunity to Francisella tularensis.
    Tärnvik A
    Rev Infect Dis; 1989; 11(3):440-51. PubMed ID: 2665002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.
    McCormick AA; Shakeel A; Yi C; Kaur H; Mansour AM; Bakshi CS
    PLoS One; 2018; 13(4):e0194614. PubMed ID: 29684046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.
    Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S
    Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.
    Jia Q; Bowen R; Dillon BJ; Masleša-Galić S; Chang BT; Kaidi AC; Horwitz MA
    Sci Rep; 2018 May; 8(1):7009. PubMed ID: 29725025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain.
    Elkins KL; Cowley SC; Bosio CM
    Microbes Infect; 2003 Feb; 5(2):135-42. PubMed ID: 12650771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mice sublethally infected with Francisella novicida U112 develop only marginal protective immunity against systemic or aerosol challenge with virulent type A or B strains of F. tularensis.
    Shen H; Chen W; Conlan JW
    Microb Pathog; 2004 Aug; 37(2):107-10. PubMed ID: 15312850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress, challenges, and opportunities in Francisella vaccine development.
    Elkins KL; Kurtz SL; De Pascalis R
    Expert Rev Vaccines; 2016 Sep; 15(9):1183-96. PubMed ID: 27010448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tularemia vaccines.
    Putzova D; Senitkova I; Stulik J
    Folia Microbiol (Praha); 2016 Nov; 61(6):495-504. PubMed ID: 27194547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominance of human innate immune responses in primary Francisella tularensis live vaccine strain vaccination.
    Fuller CL; Brittingham KC; Hepburn MJ; Martin JW; Petitt PL; Pittman PR; Bavari S
    J Allergy Clin Immunol; 2006 May; 117(5):1186-8. PubMed ID: 16675351
    [No Abstract]   [Full Text] [Related]  

  • 16. The tularaemia vaccine.
    Sandström G
    J Chem Technol Biotechnol; 1994 Apr; 59(4):315-20. PubMed ID: 7764815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Francisella tularensis vaccines.
    Griffin KF; Oyston PC; Titball RW
    FEMS Immunol Med Microbiol; 2007 Apr; 49(3):315-23. PubMed ID: 17316369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virulence determinants and protective antigens of Francisella tularensis.
    Sjöstedt A
    Curr Opin Microbiol; 2003 Feb; 6(1):66-71. PubMed ID: 12615222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a Multivalent Subunit Vaccine against Tularemia Using Tobacco Mosaic Virus (TMV) Based Delivery System.
    Banik S; Mansour AA; Suresh RV; Wykoff-Clary S; Malik M; McCormick AA; Bakshi CS
    PLoS One; 2015; 10(6):e0130858. PubMed ID: 26098553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines against Francisella tularensis.
    Wayne Conlan J; Oyston PC
    Ann N Y Acad Sci; 2007 Jun; 1105():325-50. PubMed ID: 17395730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.